Medis
Marko Stajdohar currently serves as the Chief Executive Officer at SkinPharma since June 2024. Prior to this role, Stajdohar was a Key Account Manager AE at Medis from April 2022 to August 2024, where responsibilities included the distribution of Merz Aesthetics products in Croatia and surrounding countries, relationship management with key customers, and sales target achievement. From September 2014 to April 2022, Stajdohar worked at Ottobock, initially as a Product Manager focusing on prosthetics, and subsequently as a Key Account Manager SEE, where duties encompassed business development and customer support across several Southeast European markets. Stajdohar began a professional career as a Sales Specialist and also gained experience as an Estimator at Seamless Mechanical NYC from 2012 to 2013. Educational qualifications include a degree from the University of Zagreb and health-related studies at Zdravstveno Veleuciliste Zagreb.
This person is not in any offices
Medis
1 followers
For 34 years, we have been collaborating with global pharma and biotech partners to bring innovative therapies to patients in Central and Eastern Europe. Despite the region's challenging healthcare systems and complex yet promising markets, our team of 400 employees harnesses its expertise to ensure health equity in these underserved markets. Medis is a member of the World Orphan Drug Alliance (WODA) – a global alliance of full-service regional distributors for orphan and debilitating disease products. WODA covers 152 countries in the following regions: Central and Eastern Europe, Greater China, Israel, Greece, Malta, Cyprus, Latin America, the Middle East, North Africa & Turkey, Switzerland, Australia, New Zealand and South East Asia. Out-licensing: Become our commercialization partner and benefit from advanced, ready-to-launch consumer health products, which are already marketed in 20 countries and are further expanding. More information: www.medis.com/en/international-business/ Our business areas: • Therapeutics • Hospital Care • Consumer Health • Aesthetics Our value to partners: • Direct local presence in 18 CEE countries • Full commercialization • Single point of contact and delivery • Strategic and localized market access approach • Highest compliance standards • Financial and credit excellence Major Partners: • Therapeutics: Bial – Biogen – Besins – HRA Pharma – Mundipharma – Pierre Fabre – Santen – UCB • Hospital Care: Abbott – Aesculap – Asahi Medical – Biotest – B. Braun – Cytosorbents – Paion • Consumer Health: Pleuran – Ricerpharma – Karo Healthcare – Merz – Pohl Boskamp – UP – URGO • Aesthetics: Merz Aesthetics – Crown Aesthetics • Out-licensing partners: Ferrer – Pharmalink – Sarantis – Stada